Patents Assigned to Legend Biotech USA Inc.
  • BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA
    Publication number: 20230270786
    Abstract: Provided herein are methods of treating a subject who has multiple myeloma with a ciltacabtagene autoleucel suspension. Also provided are pharmaceutical products containing ciltacabtagene autoleucel suspensions, instructions for use of the ciltacabtagene autoleucel suspensions, and methods for selling a drug product containing ciltacabtagene autoleucel suspensions.
    Type: Application
    Filed: February 27, 2023
    Publication date: August 31, 2023
    Applicants: JANSSEN BIOTECH, INC., NANJING LEGEND BIOTECH CO., LTD., LEGEND BIOTECH USA INC.
    Inventors: Xiaohu FAN, Jordan SCHECTER, Lida PACAUD, Michael HIRSCHMANN
  • Chimeric antigen receptors targeting BCMA and methods of use thereof
    Patent number: 11535677
    Abstract: Provided herein are single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) having one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) having the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: December 27, 2022
    Assignee: LEGEND BIOTECH USA INC.
    Inventors: Xiaohu Fan, Qiuchuan Zhuang, Pingyan Wang, Lin Wang, Lei Yang, Jiaying Hao, Dan Zhao, Xian He
  • CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF
    Publication number: 20220127371
    Abstract: The present application provides single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
    Type: Application
    Filed: November 3, 2021
    Publication date: April 28, 2022
    Applicant: Legend Biotech USA Inc.
    Inventors: Xiaohu FAN, Qiuchuan ZHUANG, Pingyan WANG, Lin WANG, Lei YANG, Jiaying HAO, Dan ZHAO, Xian HE
  • Chimeric antigen receptors targeting BCMA and methods of use thereof
    Patent number: 11186647
    Abstract: The present application provides single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
    Type: Grant
    Filed: February 4, 2021
    Date of Patent: November 30, 2021
    Assignee: LEGEND BIOTECH USA INC.
    Inventors: Xiaohu Fan, Qiuchuan Zhuang, Pingyan Wang, Lin Wang, Lei Yang, Jiaying Hao
  • CHIMERIC ANTIGEN RECEPTORS BASED ON SINGLE-DOMAIN ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210261675
    Abstract: The present application provides single-domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains each comprising a single-domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
    Type: Application
    Filed: February 1, 2021
    Publication date: August 26, 2021
    Applicant: Legend Biotech USA Inc.
    Inventors: Xiaohu FAN, Chuan-Chu CHOU, Qiuchuan ZHUANG, Pingyan WANG, Lin WANG, Lei YANG, Jiaying HAO
  • CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF
    Publication number: 20210163615
    Abstract: The present application provides single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
    Type: Application
    Filed: February 4, 2021
    Publication date: June 3, 2021
    Applicant: Legend Biotech USA Inc.
    Inventors: Xiaohu FAN, Qiuchuan ZHUANG, Pingyan WANG, Lin WANG, Lei YANG, Jiaying HAO, Dan ZHAO, Xian HE
  • Chimeric antigen receptors based on single domain antibodies and methods of use thereof
    Patent number: 10934363
    Abstract: The present application provides single-domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains each comprising a single-domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: March 2, 2021
    Assignee: Legend Biotech USA Inc.
    Inventors: Xiaohu Fan, Chuan-Chu Chou, Qiuchuan Zhuang, Pingyan Wang, Lin Wang, Lei Yang, Jiaying Hao